Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).

Abstract excerpt

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are among the most frequent oncogenic drivers in cancer, particularly in non‑small cell lung cancer (NSCLC). KRAS was previously considered an 'undruggable' target due to the protein's smooth molecular surface and the absence of obvious drug binding sites. However, the development of selective KRAS G12C inhibitors, such as sotorasib and adagrasib,...

Topics

Join the communities discussing this publication.

• Antineoplastic Combined Chemotherapy Protocols
• Carcinoma, Non-Small-Cell Lung
• Drug Resistance, Neoplasm
• Immunotherapy
• Lung Neoplasms